Stocks of the Hour: Mesoblast, Andromeda Metals, Imugene
Stocks of the Hour: Mesoblast, Andromeda Metals, Imugene
Mesoblast (ASX:MSB; Nasdaq:MESO) announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor, a Rare Pediatric Disease (RPD) Designation. This follows the submission of results from the randomised controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life threatening congenital heart condition. Shares are trading 18.87 per cent higher at 31.5 cents
Mesoblast（澳大利亚证券交易所股票代码：MSB；纳斯达克股票代码：MESO）宣布，美国食品药品监督管理局（FDA）已授予其异体细胞疗法Revascor罕见儿科疾病（RPD）称号。在此之前，针对左心发育不全综合症（HLHS）（一种可能危及生命的先天性心脏病）患儿的随机对照试验结果提交了结果。股价上涨18.87％，至31.5美分
Andromeda Metals (ASX:ADN) has entered into a sales and distribution agreement (Agreement) for Andromeda's high-quality kaolin products into the Mediterranean region, with IberoClays SLU. Under the Agreement, the parties agree to terms for the sale and purchase of the following: Great White CRM for sale into the ceramics and tile sectors, and Great White HRM for sale into the concrete industry. Shares are trading flat at 2.6 cents.
仙女座金属（澳大利亚证券交易所股票代码：ADN）已与IberoClays SLU签订了向地中海地区销售和分销仙女座高岭土产品的销售和分销协议（协议）。根据该协议，双方同意以下产品的销售和购买条款：向陶瓷和瓷砖行业出售Great White CRM，向混凝土行业出售Great White HRM。股价持平至2.6美分。
Imugene (ASX:IMU) has announced that its Phase 1 MAST (metastatic advanced solid tumours) trial, evaluating the safety of novel cancer-killing virus, has continued to progress with the first patients dosed in each arm of the higher dose cohort as part of the Phase 1 study. In the trial, 24 patients to date dosed in monotherapy arms with no safety issues observed, and 38 patients enrolled in trial to date across monotherapy and combination arms. Shares are trading 7.5 per cent higher at 10.75 cents.
Imugene（澳大利亚证券交易所股票代码：IMU）宣布，其评估新型杀癌病毒安全性的1期MAST（晚期转移性实体瘤）试验继续取得进展，作为1期研究的一部分，高剂量队列的每个组均为首批患者给药。在该试验中，迄今为止，有24名患者在单一疗法组中给药，未观察到任何安全问题，迄今为止，有38名患者参加了单一疗法和联合疗法组的试验。股价上涨7.5％，至10.75美分。
译文内容由第三方软件翻译。